Figure S2.

Sequential combination analysis of PHA-767491 with drugs constituting standard of care. MM1S cells were treated with Melphalan (Range 2 to 32 µM, A) Doxorubicin (Range 31 to 500 nM, B) Bortezomib (Range 1.3 to 20 nM, C) for 3 h followed by treatment with PHA-767491 in a non-constant ratio. Cell viability was examined by CellTiter Glo 48 h after drug treatment. Combination indices (CI) were calculated and the Log CI (circles) plotted in relation to the fraction of cells affected (Fa) at any given experimental point.